tadalafil has been researched along with guanosine monophosphate in 2 studies
| Studies (tadalafil) | Trials (tadalafil) | Recent Studies (post-2010) (tadalafil) | Studies (guanosine monophosphate) | Trials (guanosine monophosphate) | Recent Studies (post-2010) (guanosine monophosphate) |
|---|---|---|---|---|---|
| 1,742 | 392 | 1,089 | 1,526 | 20 | 325 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cockrill, BA; Ruopp, NF | 1 |
| Skoularigis, J; Starling, RC; Triposkiadis, F; Xanthopoulos, A | 1 |
2 review(s) available for tadalafil and guanosine monophosphate
| Article | Year |
|---|---|
Diagnosis and Treatment of Pulmonary Arterial Hypertension: A Review.
Topics: Adult; Antihypertensive Agents; Endothelin Receptor Antagonists; Endothelins; Guanosine Monophosphate; Heart Failure; Humans; Hypertension, Pulmonary; Infant, Newborn; Nitric Oxide; Pulmonary Arterial Hypertension; Tadalafil; United States | 2022 |
Therapeutic augmentation of NO-sGC-cGMP signalling: lessons learned from pulmonary arterial hypertension and heart failure.
Topics: Cyclic GMP; Cyclic Nucleotide Phosphodiesterases, Type 5; Guanosine Monophosphate; Guanylate Cyclase; Heart Failure; Humans; Nitric Oxide; Phosphodiesterase 5 Inhibitors; Pulmonary Arterial Hypertension; Retrospective Studies; Sildenafil Citrate; Soluble Guanylyl Cyclase; Tadalafil; Vasodilator Agents | 2022 |